Globe Newswire
Globe Newswire
More Globe Newswire
View Older Stories View Newer Stories-
Zevra Therapeutics Reports First Quarter 2024 Financial Results and Corporate Updates
-
GDS to Report First Quarter 2024 Financial Results Before the Open of the U.S. Market on May 22, 2024
-
OKYO Pharma Announces Participation in May 2024 Investor Conferences
-
PolyPid Provides Corporate Update and Reports First Quarter 2024 Financial Results
-
Inception Growth Acquisition Limited Announces Additional Contribution to Trust Account to Extend Business Combination Period
-
Chemomab Therapeutics Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Rule
-
Village Farms International Reports Strong Q1/24 Results
-
Multi Ways Holdings Expands Fleet with the Acquisition of 16 New Crawler Cranes
-
Axsome Therapeutics to Present at Upcoming Investor Conferences
-
Akero Therapeutics to Present at the BofA Securities 2024 Health Care Conference
-
Stella-Jones Announces First Quarter Results
-
Mayfair Gold Provides Update on Fenn-Gib Gold Project
-
Verve Therapeutics Announces Pipeline Progress and Reports First Quarter 2024 Financial Results
-
EcoSafi announces the first issuance of carbon credits in Africa under high-integrity Gold Standard MECD methodology
-
Gen II Announces The Rebranding of its Portal to Sensr Portal
-
Editas Medicine Announces First Quarter 2024 Results and Business Updates
-
C4 Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights
-
Kaltura Announces Financial Results for First Quarter 2024
-
REE Automotive Continues to Expand Full by-Wire EV Offering at ACT Expo 2024
-
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Plug
-
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Ocugen
-
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Luna
-
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Innoviz
-
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Evolv
-
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Anavex
-
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Checkpoint
-
CRISPR Therapeutics Highlights ASGCT Oral Presentation and Announces New Programs Utilizing In Vivo Gene Editing Approach
-
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Chemours
-
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Blue
-
Kymera Therapeutics to Participate in Upcoming May Investor Conferences
-
Omega Therapeutics Presents New Preclinical Data at ASGCT 2024 Demonstrating Tunable and Durable Upregulation of Gene Expression with Epigenomic Controllers
-
Achilles Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights
-
1stDibs Reports First Quarter 2024 Financial Results
-
More Than 90% of Metro Areas Recorded Home Price Increases in First Quarter of 2024
-
Kojamo plc Interim Report 1 January–31 March 2024
-
Immunocore reports first quarter financial results and provides a business update
-
Krystal Biotech to Present at BofA Securities 2024 Health Care Conference
-
MIND CTI Reports First Quarter 2024 Results
-
AvidXchange Announces First Quarter 2024 Financial Results
-
Brookfield Asset Management Announces Strong First Quarter Results
-
Compass Pathways Announces First Quarter 2024 Financial Results and Business Highlights
-
Cellectar Biosciences to Present at the Guggenheim Healthcare Talks Radiopharmaceuticals Day
-
Temenos Multifonds extends partnership with Citi Securities Services to consolidate global funds services on Multifonds SaaS
-
Ducommun Incorporated Reports First Quarter 2024 Results
-
Azimut and SOQUEM Cut Very High Grade Lithium Drill Intercepts on Galinée, James Bay Region, Quebec
-
Veru Reports Fiscal 2024 Second Quarter Financial Results and Progress of its Enobosarm High Quality Weight Loss Clinical Program
-
Kraken Robotics Receives $3.5 Million of Orders for Subsea Security Equipment
-
Beam Therapeutics to Participate in RBC Capital Markets 2024 Global Healthcare Conference
-
Compass Pathways announces durable improvement in symptoms through 12 weeks in open-label phase 2 study of COMP360 psilocybin in post-traumatic stress disorder
-
Form 8.3 - Tyman plc


